| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 42,387 | 88,426 | ||
| Short-term investments | 34,612 | - | ||
| Prepaid expenses and other current assets | 1,184 | 3,225 | ||
| Total current assets | 78,183 | 91,651 | ||
| Deferred transaction costs | 0 | 0 | ||
| Operating lease right-of-use assets | 1,516 | - | ||
| Restricted cash | 500 | 500 | ||
| Other non-current assets | 976 | 691 | ||
| Total assets | 81,175 | 92,842 | ||
| Accounts payable | 494 | 3,680 | ||
| Convertible promissory notes, net of discount of 1,298 (including 0 and 18,670 due to a related party) | 0 | 0 | ||
| Derivative liabilities (including 0 and 995 due to a related party) | 0 | 0 | ||
| Tranche liability (including 0 and 331 due to a related party) | 0 | 0 | ||
| Accrued expenses and other current liabilities (including 64 and 85 due to a related party) | 5,195 | 3,971 | ||
| Operating lease liabilities, current | 376 | - | ||
| Total current liabilities | 6,065 | 7,651 | ||
| Royalty obligation - related party | 32,076 | 32,076 | ||
| Operating lease liabilities, long-term | 1,169 | - | ||
| Total liabilities | 39,310 | 39,727 | ||
| Common stock, 0.0001 and 0.00001 par value as of september 30, 2025 and december 31, 2024, respectively 300,000,000 and 86,000,000 shares authorized as of september 30, 2025 and december 31, 2024, respectively 18,702,418 and 1,356,431 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 2 | 2 | ||
| Additional paid-in capital | 191,858 | 191,220 | ||
| Accumulated other comprehensive income | 6 | - | ||
| Accumulated deficit | -150,001 | -138,107 | ||
| Total stockholders' equity (deficit) | 41,865 | 53,115 | ||
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | 81,175 | 92,842 | ||
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)